AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

BACKGROUND: Few prospective studies have assessed the role of bevacizumab and included a control arm with standard treatments for recurrent glioblastoma. We conducted a noncomparative phase II trial (AVAREG) to examine the efficacy of bevacizumab or fotemustine in this setting. METHODS: Eligible pat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Caserta, Claudia, Fabi, Alessandra, Clavarezza, Matteo, Maiello, Evaristo, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Proietti, Emanuela, Agati, Raffaele, Eusebi, Vincenzo, Franceschi, Enrico
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2016
Aiheet:
Clinical Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998997/
https://ncbi.nlm.nih.gov/pubmed/26951379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now035
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia